Market Cap | 1.22M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -7.08M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -21.00% |
Sales | 381k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -97.00% |
Dividend | N/A | Price/Book | 0.02 | EPS next 5Y | - | 52W High Chg | -100.00% |
Recommedations | 1.00 | Quick Ratio | 1.20 | Shares Outstanding | 4.39M | 52W Low Chg | 47.00% |
Insider Own | 9.94% | ROA | -51.38% | Shares Float | 1.19B | Beta | 1.57 |
Inst Own | 18.94% | ROE | -180.59% | Shares Shorted/Prior | 189.61K/102.63K | Price | 5.17 |
Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 348,759 | Target Price | 8.00 |
Oper. Margin | -2,843.37% | Earnings Date | - | Volume | 98,606 | Change | 0.58% |
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. In addition, the company offers licensing for MTD 201 (Q-octreotide) and MTD211 (Q-brexpiprazole). The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Ladenburg Thalmann | Buy | Feb 8, 24 |